We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Die Studie erreichte ihr Ziel beim primären Endpunkt, der Senkung des Nüchternblutzuckers – Risikofaktor für Typ-2-Diabetes, bei einer Tagesdosis von 5 g und drei Verabreichungen pro Tag mit...
The study achieved its objective on the primary endpoint, the reduction of fasting blood glucose, a risk factor for type 2 diabetes, at a 5g daily dose in 3 intakes per day, with a high...
Regulatory News: Valbiotis (FR0013254851 – ALVAL, éligible PEA / PME), entreprise de Recherche et Développement à dimension commerciale, engagée dans l’innovation scientifique, pour la prévention...
Regulatory News: Valbiotis (FR0013254851 – ALVAL, éligible PEA / PME) (Paris:ALVAL), entreprise de Recherche et Développement à dimension commerciale, engagée dans l’innovation scientifique, pour...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.09 | -2.2641509434 | 3.975 | 3.98 | 3.65 | 14340 | 3.87940914 | DE |
4 | 0.245 | 6.73076923077 | 3.64 | 4.145 | 3.44 | 33394 | 3.84889542 | DE |
12 | -0.315 | -7.5 | 4.2 | 4.44 | 3.41 | 31292 | 3.97833535 | DE |
26 | -2.495 | -39.1065830721 | 6.38 | 7.34 | 3.41 | 45782 | 4.89690106 | DE |
52 | 0.105 | 2.77777777778 | 3.78 | 7.5 | 2.82 | 49880 | 4.9425863 | DE |
156 | -4.135 | -51.5586034913 | 8.02 | 8.04 | 2.82 | 22867 | 5.14401191 | DE |
260 | -0.145 | -3.59801488834 | 4.03 | 8.38 | 1.98 | 21455 | 4.93053902 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions